VEA
OLMA icon

Virtus ETF Advisers’s Olema Pharmaceuticals OLMA Stock Holding History

Virtus ETF Advisers’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,579
Closed -$61.7K – 675
2024
Q4 		$61.7K Buy
10,579
+3,185
+43% +$31.8K 0.03% 442
2024
Q3 		$88.3K Buy
7,394
+129
+2% +$1.65K 0.04% 393
2024
Q2 		$78.6K Buy
7,265
+235
+3% +$2.55K 0.04% 410
2024
Q1 		$79.6K Sell
7,030
-485
-6% -$6.26K 0.04% 394
2023
Q4 		$105K Buy
+7,515
New +$101K 0.07% 337
2022
Q2 		– Sell
-17,135
Closed -$73K – 462
2022
Q1 		$73K Sell
17,135
-1,015
-6% -$5.59K 0.03% 346
2021
Q4 		$170K Buy
18,150
+11,036
+155% +$229K 0.06% 285
2021
Q3 		$196K Sell
7,114
-365
-5% -$9.85K 0.09% 276
2021
Q2 		$209K Buy
+7,479
New +$213K 0.09% 316

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

Virtus ETF Advisers's OLMA Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Olema Pharmaceuticals (OLMA) in Q1 2025, closing a stake of 10,579 shares — an estimated $61.7K sold.

Virtus ETF Advisers first reported a position in OLMA in Q2 2021 and held it in 9 quarters. The position peaked at $209K in Q2 2021. 133 funds tracked by Wall St. Rank hold OLMA as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Olema Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 10,579 Olema Pharmaceuticals shares in Q1 2025, an estimated $61.7K.
  • Virtus ETF Advisers first reported a position in Olema Pharmaceuticals in Q2 2021 and held it in 9 quarters.
  • Virtus ETF Advisers's Olema Pharmaceuticals position peaked at $209K in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.